Absci Corporation (NASDAQ:ABSI) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT
Company Participants
Sean McClain – Founder, CEO, President & Director
Zachariah Jonasson – Chief Business Officer & CFO
Conference Call Participants
Sean Laaman – Morgan Stanley, Research Division
Presentation
Sean Laaman
Head of Healthcare Research & Equity Analyst
Good afternoon, everyone, and welcome to Morgan Stanley’s Global Healthcare Conference. I’m Sean Laaman, Head of U.S. MidCap biotech equity research. Getting late in the day. But for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/research disclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. Right. For this session, we have Absci with the founder CEO and Director, Sean McClain, and CFO and Chief Business Officer, Zach Jonasson. But welcome gentlemen.
Question-and-Answer Session
Sean Laaman
Morgan Stanley, Research Division
And maybe just to kick off proceeding, Sean, contextualize the discussion and give us a bit of a view on Absi.
Sean McClain
Founder, CEO, President & Director
Yes, definitely. So we’re a generative design company really leveraging AI to be able to go after the hardest and most challenging problems that still exist being able to go after hard targets such as ion channels and GPCRs, the undruggable targets. We think of AI as being able to decrease time lines and decrease overall cost, but it also opens up kind of the fourth dimension, which is being able to unlock new novel biology where other technologies are unable to address.
And you see that in our partnerships with Merck and AstraZeneca and Almirall, but also in our own internal pipeline as well. We have a portfolio that’s focused on I&I. The first asset is in the clinic. We’ll have a Phase Ia readout in the coming months. And then additionally, we’ll
#Absci #Corporation #ABSI #Morgan #Stanley #Annual #Global #Healthcare #Conference #Transcript